R&D Incentives Awarded By FDA, Not Patents, Suggested In Health Affairs
Policy efforts to balance incentives for research and development with free-market competition may be more successful if they focus on FDA regulation rather than the patent system, an article in the September/ October issue of Health Affairs suggests.
You may also be interested in...
A National Pharmaceutical Council-funded analysis of the value of newer medicines will give brand name pharmaceutical companies additional evidence to argue that the cost of a Medicare prescription drug benefit may be offset by savings in other health spending.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials